Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00410228
First received: December 11, 2006
Last updated: June 21, 2007
Last verified: June 2007
  Purpose

This study will evaluate the safety and tolerability of ascending single oral doses of AHT956 in healthy subjects


Condition Intervention Phase
Healthy
Drug: AHT956
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Single Center, Randomized, Double-Blind, Placebo-and Positive-Controlled, Interleaved, Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHTT956 in Healthy Subjects

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Safety, tolerability of ascending single doses of AHT956 in healthy subjects
  • MTD (Maximum Tolerated Dose)

Secondary Outcome Measures:
  • Pharmacokinetics of single oral doses of AEB071
  • Inhibition of T-cell function and lymphocytes proliferation following single rising oral of AHT956
  • Pharmacokinetic/pharmacodynamic relationship of single rising oral doses of AHT956 at the end of study
  • Identify gene expression patterns of blood cells

Estimated Enrollment: 42
Study Start Date: June 2006
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female subjects age 18 to 45 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
  • Vital signs must be within the following ranges: oral body temperature between 35.0-37.5 °C; systolic blood pressure, 90-145 mm Hg; diastolic blood pressure, 50-95 mm Hg; pulse rate, 40-90 bpm
  • Female subjects must either:have been surgically sterilized or hysterectomized at last 6 months prior to study participation with clinical documentation be postmenopausal (no regular menstrual bleeding for at least 1 year prior to study start)
  • Body mass index must be within the range of 18 to 28 kg/m². Subjects must weigh at least 50 kg to participate in this study.

Exclusion Criteria:

  • Smokers (any subject who uses tobacco or has cotinine greater than 500 ng/mL)).
  • Subjects who received live vaccine 4 weeks prior to dosing, any prescription drug use with 4 weeks prior to dosing, or over-the-counter medication use within 2 weeks prior to dosing.
  • Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
  • Flu-like symptoms or significant within two weeks prior to dosing.
  • A past medical history of clinically significant abnormality detected during electrocardiogram (ECG) examination or an evident family history (grandparents, parents and siblings) of a ECG abnormality (i.e. prolonged QT-interval syndrome).
  • History of fainting, hypotension when standing up, arrhythmia.
  • History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
  • History of clinically significant drug allergy or history of atopic allergy, urticaria, eczematous dermatitis). A known hypersensitivity to the study drugs or drugs similar to the study drugs.
  • Any history of surgical or medical condition(s) which could change the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject, including history of gastrointestinal, pancreatic, liver, kidney, bladder, blood, or immune systems.
  • History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted the screening or baseline evaluations.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00410228

Locations
Switzerland
Novartis Investigative Site
Bern, Switzerland
Sponsors and Collaborators
Novartis
Investigators
Principal Investigator: Novartis Investigator site
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00410228     History of Changes
Other Study ID Numbers: CAHT956A2101
Study First Received: December 11, 2006
Last Updated: June 21, 2007
Health Authority: Switzerland: Swissmedic

Keywords provided by Novartis:
safety, tolerability, pharmacokinetics, pharmacodynamics, AHT956

ClinicalTrials.gov processed this record on August 27, 2014